Postmenopausal, oestrogen receptor (ER)-positive breast cancers account for the majority of the 1·7 million breast cancers diagnosed annually worldwide. Adjuvant endocrine therapy dramatically improves survival among such patients, making it vital to understand the best treatment strategies. For decades, the Early Breast Cancer Trialists' Collaborative Group meta-analyses have informed clinical practice in early-stage breast cancer, and the present report 1 in The Lancet on over 30 000 women treated with adjuvant tamoxifen, aromatase inhibitors, or a sequence of those agents continues that tradition. The meta-analysis confi rms that, in comparison with tamoxifen alone, aromatase inhibitor-based therapy in the fi rst 5 years reduces the risk of recurrence (rate ratio 0·64, 95% CI 0·52-0·78, during years 0-1; 0·80, 0·68-0·93, during years 2-4) and improves overall survival at 10 years (0·89, 0·81-0·97). Sequential therapy with tamoxifen and then an aromatase inhibitor during the fi rst 5 years yielded recurrence rates that were nearly the same as those achieved with upfront aromatase inhibitor therapy, with average recurrence rates diff ering by less than 1% through 7 years of follow-up and without a survival diff erence. Because of the enormous size of the individual trials that comprised the meta-analysis-most of the primary studies enrolled between 5000 and 10 000 womenrecurrence reductions were already well established, [2] [3] [4] and clinical guidelines recommend that postmenopausal women consider aromatase inhibitor-based therapy within the fi rst 5 years of their adjuvant treatment course, either up front or sequentially after tamoxifen. [5] [6] [7] Pooled data in the overview could facilitate subset analyses when low numbers of events in individual trials might otherwise make it hard to spot benefi ts. Comparisons between drugs show that the benefi ts of aromatase inhibitor treatment are a class eff ect: there is nothing to distinguish one brand from another.
These new data challenge clinicians to ask two important questions. First, should all postmenopausal women with ER-positive breast cancer be off ered upfront aromatase inhibitor therapy as opposed to sequential treatment, and, if not, can clinical factors be identifi ed that might enable clinicians to tailor therapy? Second, how might the longer durations of endocrine therapy that are now being recommended bear on the understanding of these data? When the trials included in this meta-analysis were done, the standard duration of adjuvant endocrine therapy was 5 years. Since then, we have learned that extending adjuvant treatment beyond 5 years out to 10 years with either ongoing tamoxifen 8 or by switching to an aromatase inhibitor 9 can further reduce breast cancer recurrences. These fi ndings invite speculation that longer treatment duration with an aromatase inhibitor-longer than the 5 years studied in the meta-analysis-or a longer sequential programme would be of benefi t to patients. But, at present, there are no data from randomised trials assessing the effi cacy of these approaches. Despite extensive eff orts, there is currently no validated marker that can be used to Postmenopausal breast cancer: a best endocrine strategy? specifi cally predict which patients will benefi t from a longer duration of adjuvant endocrine treatment. The same prognostic markers that stratify patients for risk of early recurrence-stage, grade, quantitative hormone receptor expression, Ki67, intrinsic subtype, 21-gene recurrence score, and other molecular profi ling assaysare, however, also prognostic for late recurrence. 10 Since the inception of adjuvant trials of aromatase inhibitor therapy, we have learned how to integrate clinical stage with many prognostic marker analyses, including molecular profi les to risk stratify patients with ER-positive breast cancers. We have also altered the natural history of ER-positive, HER2-positive tumourshistorically and in this meta-analysis 1 among the most aggressive of ER-positive breast cancers-with use of adjuvant trastuzumab. In contemporary breast cancer management, clinicians use these well known factors to assign most women with postmenopausal ER-positive breast cancers into lower-risk or higher-risk groups. For women whose tumour stage and biology put them at the lower end of the risk recurrence spectrum-typically node-negative cancers with lower grade or proliferation features, strong expression of ER and PR, and lack of HER2 expression, usually associated with luminal A phenotype or low recurrence score molecular profi lesthe diff erences in outcomes between tamoxifen-based and aromatase inhibitor-based therapy are lower. 11 Prospective studies, not included in the meta-analysis, 1 comparing tamoxifen and aromatase inhibitor therapy among premenopausal women with lower-risk tumours, who were off ered ovarian suppression with an aromatase inhibitor or with tamoxifen but not given chemotherapy, showed small diff erences between aromatase inhibitor-based or tamoxifen-based treatment. 12, 13 For women with tumours bearing lower recurrence risk, consideration of the side-eff ect profi le and preferences of the patient are critical for choosing the initial endocrine drug. By contrast, among women at greater risk of recurrence, typically those with larger or node-positive tumours by stage, or because of adverse pathological or molecular features, it is more important to capture the relative gains of early aromatase inhibitor therapy, making it preferable to start treatment with an aromatase inhibitor. This risk-tailored approach has been specifi cally endorsed by expert consensus guidelines. 6 Those caring for women with breast cancer realise that the accompanying meta-analysis 1 is missing a key set of data: the patient experience. Women on anti-oestrogen treatments endure substantial side-eff ects, including menopausal symptoms such as hot fl ashes and night sweats. Aromatase inhibitors, in particular, are also associated with bone pain and arthralgias, vaginal dryness, sexual dysfunction, osteoporosis, bone fracture, and hair thinning. Some of these symptoms can be addressed with specifi c interventions; others prove resistant and markedly aff ect quality of life. Treatment-related symptoms are a primary determinant of patient compliance with adjuvant endocrine therapy. 14, 15 Anecdotal experience suggests that some patients tolerate aromatase inhibitors better than tamoxifen, and vice versa, and that patients intolerant of one aromatase inhibitor might tolerate another, especially after a short treatment hiatus to reset their symptom profi le. Ultimately, the best choice for adjuvant endocrine therapy is a treatment the patient is willing to take. For most patients, especially as we envision an era of longer durations of endocrine therapy, it will be more important to assure that they are on a tolerable medication than to be unyielding over prescribing a specifi c bottle that sits untouched in the medicine cabinet. 
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Bisphosphonates, bone, and breast cancer recurrence
Bisphosphonates reduce bone turnover by inhibiting osteoclast maturation and function, and are important in the prevention of age-related osteoporosis and bone fracture, 1 in the prevention of complications of bone metastases, 2 and in the prevention of osteopenia and osteoporosis resulting from adjuvant aromatase inhibitor therapy of breast cancer. 3 Over 125 years ago, in The Lancet, Paget hypothesised that the "soil" in which a tumour resides would be important for tumour propagation and growth. 4 Interruption of the interaction of tumour micrometastases with their microenvironmental "soil" is now a subject of intense investigation. Bone is an active microenvironment, and, in bone with high turnover, excess osteoclastic activity could potentially lead to excess production of growth factors, which could aff ect survival of micrometastases. 5 Bisphosphonates, by reducing osteoclast activity, could in theory reduce expression of these factors, thereby preventing establishment of micrometastatic disease.
Clinical trials of bisphosphonates as adjuvant therapy for breast cancer have had mixed results. Clodronate, an oral fi rst-generation bisphosphonate, showed a disease-free survival benefi t versus placebo in one large randomised trial, 6 but not in another. 7 An early trial of zoledronic acid, a more powerful third-generation aminobisphosphonate, added to adjuvant aromatase inhibitor therapy for postmenopausal women to prevent bone loss, showed a non-signifi cant improve ment in disease-free survival, 3 a secondary endpoint. Larger trials comparing zoledronic acid to no therapy in postmenopausal women, 8 or in premenopausal women made menopausal with gonadotropin-releasing hormone agonists, 9 showed signifi cant disease-free survival benefi ts, but no benefi t was seen in a large randomised trial of both premenopausal and postmenopausal women. 10 In The Lancet, the Early Breast Cancer Trialists' Collaborative Group 11 presents a meta-analysis of randomised trials of bisphosphonates as adjuvant systemic therapy for breast cancer. This meta-analysis is comprised of individual patient data derived from randomised adjuvant bisphosphonate trials in breast cancer done over the past 20 years. The analysis received data on 18 766 women (18 206 in randomised trials of 2-5 years of adjuvant bisphosphonate vs control), with a median follow-up of 5·6 years, 3453 fi rst recurrences, and 2106 deaths. For all patients, there were borderline signifi cant reductions with the addition of bisphosphonates at 10 years for distant recurrence (20·4% vs 21·8%, rate ratio [RR]=0·92, 95% CI 0·85-0·99; 2p=0·03), bone recurrence (7·8% vs 9·0%, RR=0·83, 0·73-0·94; 2p=0·004), breast cancer mortality (16·6% vs 18·4%, RR=0·91, 0·83-0·99; 2p=0·04), and all-cause mortality (20·8% vs 22·3%, RR=0·92, 0·85-1·00; 2p=0·06).
